Biomedevice Boston 2020 Presentation Store
Welcome to the Biomedevice Boston Presentation Store. Here you can view and download conference presentations before, during, and after the event, as well as free content from the Center Stage. If you’re looking for a presentation from a specific session, go to that session, and if we have the presentation to share, you’ll see the file below the session description. If you are unable to find it here, it’s likely because the presenter has not provided permission for external use or has not yet shared their presentation with us. Please check back after the event for a more complete catalogue of available presentations.
Devon Campbell, CPO, Head of R&D, MyBiometry
As Chief Product Officer, Devon leads research, development, and quality at myBiometry, a digital health and device company focused on remotely monitoring chronic conditions using software and biomarker data generated from proprietary sensors and readers. The company's initial focus is asthma where it uses breath-based biomarker detection to determine adherence, the efficacy of medication, and risk exacerbation.
Devon is actively advising several Biotech and Medtech start-ups directly, through Advisory Boards, or on Boards of Directors. Most recently, Devon joined the Board of Directors for MasksOn.org, a non-profit medical device effort focused on mass-producion and donation of reusable, sanitizable Emergency Use Authorized face shields to clinicians and front-line heroes supporing COVID-19 patients but faced with limited personal protective equipement (PPE).
Devon is also the founder of Prodct LLC, a Boston-based, boutique advisory firm focused on helping emerging entrepreneurs and early-stage biotech, medical device, diagnostic, and therapeutic companies create and execute expedited product development and commercialization strategies.
Before myBiometry and Prodct, Devon led product development and engineering at several successful medical device and diagnostic companies over the last 21+ years including Quanterix ($74M IPO in 2017), Novartis Companion Diagnostics (acquired Genoptix for $740M in 2011 + Vivacta for $90M in 2012), and Ventana Medical Systems ($3.4B acquisition by Roche in 2008).